News & Updates

Show Multimedia Only

COVID-linked MIS-C outcomes reassuring at 6 months

31 Jan 2025 by

Children and young adults with multisystem inflammatory syndrome in children (MIS-C) related to COVID-19 infection show good cardiovascular and noncardiovascular outcomes at 6 months, according to data from the long-term MUSIC study.

COVID-linked MIS-C outcomes reassuring at 6 months

31 Jan 2025

Study supports continued metformin use in T2D patients with advanced kidney disease

31 Jan 2025

For patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), continued use of metformin for at least 6 months when eGFR falls below 30 mL/min/1.73m2 appears to yield a small but significant decrease in all-cause mortality, according to a nationwide observational cohort study.

Study supports continued metformin use in T2D patients with advanced kidney disease

31 Jan 2025

Determinants of semaglutide initiation in obesity

30 Jan 2025

In people with obesity but without diabetes, starting semaglutide treatment appears to be influenced by sociodemographic, health care, and clinical factors, according to a retrospective observational cohort study.

Determinants of semaglutide initiation in obesity

30 Jan 2025

Gabapentin tied to fewer falls in older adults vs duloxetine

30 Jan 2025

The incident use of gabapentin, compared with duloxetine, does not seem to increase fall-related visits among older adults, according to a study.

Gabapentin tied to fewer falls in older adults vs duloxetine

30 Jan 2025

Metallic better than polymeric stents for CUO management

30 Jan 2025 by

The use of Resonance metallic stent (MS) for chronic ureteric obstruction (CUO) leads to markedly longer indwelling time that prevents the higher unit cost of the stent when compared with the conventional polymeric stent (PS), reports a study in Singapore.

Metallic better than polymeric stents for CUO management

30 Jan 2025

Denosumab vs oral bisphosphonates: Which is safer in patients receiving dialysis?

30 Jan 2025

Among patients on dialysis, the use of denosumab reduced the risk for fractures by as much as 45 percent but increased the risk for major adverse cardiovascular events (MACE) by 36 percent when compared with oral bisphosphonates, a study has shown.

Denosumab vs oral bisphosphonates: Which is safer in patients receiving dialysis?

30 Jan 2025

Chamomile helps with menopausal symptoms

30 Jan 2025

Herbal intervention with Matricaria chamomilla, known as chamomile, appears to alleviate menopausal symptoms, as shown in the results of a triple-blind clinical trial.

Chamomile helps with menopausal symptoms

30 Jan 2025

Pembrolizumab–bevacizumab combo works against nasopharyngeal carcinoma

29 Jan 2025

The combination of pembrolizumab plus bevacizumab shows promising activity against platinum-resistant nasopharyngeal carcinoma while having manageable toxicities, according to an open-label phase II study conducted in Singapore.

Pembrolizumab–bevacizumab combo works against nasopharyngeal carcinoma

29 Jan 2025

Empagliflozin, dapagliflozin in a draw for renoprotection in T2D

29 Jan 2025 by

Long-term kidney outcomes in type 2 diabetes (T2D) are similar between empagliflozin- and dapagliflozin-treated patients, aligning with current clinical practice guidelines that do not favour one SGLT2 inhibitor over the other, according to a study.

Empagliflozin, dapagliflozin in a draw for renoprotection in T2D

29 Jan 2025

GLP-1 RAs reduce BP in overweight, obese patients

29 Jan 2025

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly lowers blood pressure (BP) in obese or overweight patients, according to a study. This beneficial effect persists across diabetic status, duration of treatment, and route of administration.

GLP-1 RAs reduce BP in overweight, obese patients

29 Jan 2025

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

COVID-linked MIS-C outcomes reassuring at 6 months

COVID-linked MIS-C outcomes reassuring at 6 months

Study supports continued metformin use in T2D patients with advanced kidney disease

Study supports continued metformin use in T2D patients with advanced kidney disease

Determinants of semaglutide initiation in obesity

Determinants of semaglutide initiation in obesity

Gabapentin tied to fewer falls in older adults vs duloxetine

Gabapentin tied to fewer falls in older adults vs duloxetine

Metallic better than polymeric stents for CUO management

Metallic better than polymeric stents for CUO management

Denosumab vs oral bisphosphonates: Which is safer in patients receiving dialysis?

Denosumab vs oral bisphosphonates: Which is safer in patients receiving dialysis?

Chamomile helps with menopausal symptoms

Chamomile helps with menopausal symptoms

Pembrolizumab–bevacizumab combo works against nasopharyngeal carcinoma

Pembrolizumab–bevacizumab combo works against nasopharyngeal carcinoma

Empagliflozin, dapagliflozin in a draw for renoprotection in T2D

Empagliflozin, dapagliflozin in a draw for renoprotection in T2D

GLP-1 RAs reduce BP in overweight, obese patients

GLP-1 RAs reduce BP in overweight, obese patients